Purple Biotech Ltd - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PPBT Nasdaq 2834 purple-biotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Purple Biotech Ltd

Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT) - Jun 11th, 2026 8:38 am
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window - Jun 11th, 2026 5:00 am
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights - May 15th, 2026 5:00 am
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 - Apr 27th, 2026 5:00 am
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform - Apr 23rd, 2026 5:00 am
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform - Mar 25th, 2026 6:00 am
Purple Biotech Regains Compliance with Nasdaq - Mar 17th, 2026 5:00 am
Purple Biotech Announces CEO Transition - Mar 13th, 2026 6:04 am
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 13th, 2026 6:00 am
Purple Biotech Announces Plan to Implement ADS Ratio Change - Feb 25th, 2026 2:20 pm
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 - Jan 7th, 2026 6:00 am
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 - Dec 11th, 2025 5:00 am
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress - Dec 4th, 2025 5:00 am
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 14th, 2025 6:00 am
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform - Oct 29th, 2025 5:33 am
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance - Sep 10th, 2025 6:00 am
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants - Sep 5th, 2025 2:00 pm
Purple Biotech Announces Pricing of Up To $18 Million Public Offering - Sep 4th, 2025 7:15 am
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai - Sep 4th, 2025 5:00 am
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 - Sep 3rd, 2025 5:00 am